Advancing treatment for high-risk biochemical recurrence #ProstateCancer. Alex Chehrazi-Raffle, MD @cityofhop sits with Zach Klaassen Georgia Cancer Center to discuss the #ARASTEP trial of ADT + Darolutamide vs. ADT alone on UroToday > bit.ly/4d2DgsD

The Impact of advanced imaging on detection and treatment in nonmetastatic #CRPC. Vahan Kassabian Advanced Urology joins Zach Klaassen @GACancerCenterr in a discussion on the evolving landscape of #nmCRPC management > bit.ly/3UvcvGA Bayer U.S. 🇺🇸

Daniel Saltzstein, MD Urology San Antonio joins Zach Klaassen Georgia Cancer Center to discuss the collaborative strategy for treating #mHSPC 🤝 He emphasizes clear communication and a multidisciplinary team for optimal patient outcomes > bit.ly/3w5kC2N Bayer U.S. 🇺🇸

Best practices for successfully implementing triplet therapy in #mHSPC. Chris Pieczonka AMP and Zach Klaassen Georgia Cancer Center discuss managing mHSPC emphasizing the shift from ADT monotherapy to triple therapy. #WatchNow > bit.ly/3UndFUb

Navigating the Nuances: Exploring imaging options and impact to treatment strategies in #nmCPRC. Ryan Malone, MD First Urology joins Zach Klaassen Georgia Cancer Center in this conversation focusing on the evolving role of PSMA PET imaging. #WatchNow > bit.ly/42lRAaT Bayer U.S. 🇺🇸

Maximizing survival in #mHSPC: The role of triplet therapy. Kelvin Moses, MD, PhD Vanderbilt-Ingram Cancer Center joins Zach Klaassen Georgia Cancer Center to discuss the ideal patient profile and emphasize collaboration between #Urology and #MedicalOncology > bit.ly/4b06kzn

Bladder-sparing chemoradiation for localized #BladderCancer: addressing the unmet need. Brent Rose, MD UC San Diego joins Zach Klaassen Georgia Cancer Center to discuss advances in bladder-sparing therapies for localized bladder cancer > bit.ly/4coCw0D

Implementing nadofaragene firadenovec treatment in #NMIBC. Mark Tyson, Aimee Boden, & Meghann Davis Mayo Clinic join Zach Klaassen Georgia Cancer Center to discuss implementation and logistics and the importance of a comprehensive and collaborative approach > bit.ly/3TJBlk3

Building an integrated, multidisciplinary team to optimize care for patients with #mHSPC 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Norton Healthcare & Ryan Malone, MD First Urology join Zach Klaassen Georgia Cancer Center discuss comanagement in these complex cases > bit.ly/484wWgM Bayer U.S. 🇺🇸

Welcome letter from the advanced #ProstateCancer Center of Excellence editor - Zach Klaassen Georgia Cancer Center. As #PCa treatments evolve rapidly, UroToday is your go-to resource for the latest updates, expert insights, and educational content. #StayTuned! bit.ly/4g6jjTv

Managing nonmetastatic castration-resistant #ProstateCancer. Zachary Reardon, MD joins Zach Klaassen Georgia Cancer Center to discuss the nuances of managing #nmCRPC in clinical practice. #WatchNow > bit.ly/43Q6KGr

Communication for optimal care in patients selected for triplet therapy between #Urology and community oncology. Vahan Kassabian & Sreekanth Reddy, MD, join Zach Klaassen to discuss the continuum of care for patients with #mHSPC > bit.ly/47V4tKm American Oncology Network Bayer U.S. 🇺🇸

Care for patients with nonmetastatic castration-resistant #ProstateCancer. Hanan Goldberg Upstate Urology and Zach Klaassen Georgia Cancer Center discuss this evolving landscape and the impact of PSMA PET scans on diminishing this patient category. #WatchNow > bit.ly/3uZ9nJ1

Dive into the latest insights on #ProstateCancer treatment with Kae Jack Tay and Zach Klaassen! Discover the current state of #FocalTherapy in #PCa and its epidemiological impacts. Essential viewing for urologists and healthcare professionals! #WatchNow > bit.ly/3K5d6Zl

National Comprehensive Cancer Network (NCCN) 2024 #ProstateCancer guidelines update: PARP inhibitors in focus. Rashid K. Sayyid and Zach Klaassen discuss non-hormonal systemic therapy, highlighting significant changes, particularly the emergence of PARP inhibitors like olaparib and rucaparib > bit.ly/3We9KKj

The #STEEL trial: Evaluating enzalutamide + ADT with salvage RT for high-risk recurrent #ProstateCancer. Edwin Posadas, MD Cedars-Sinai joins Zach Klaassen Georgia Cancer Center to discuss the complexities and aspirations of this trial > bit.ly/3V0Kd70

Navigating #nmCRPC treatment in the PSMA PET era. Neal Shore, MD, FACS CURC joins Zach Klaassen Georgia Cancer Center to discuss this evolving landscape and delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. #WatchNow > bit.ly/3UHqk38

Non-metastatic CRPC in the era of PSMA PET imaging: Challenges and opportunities. Aaron Berger, MD Associated Urological Specialists joins Zach Klaassen Georgia Cancer Center to discuss the evolving landscape of #nmCRPC. #WatchNow > bit.ly/3Q5qWhy

SLICE: Revolutionizing surgical training with ultra-realistic simulation. Ahmed Ghazi joins Zach Klaassen to discuss his work in the field of his work in robotic simulation and his journey from laparoscopic surgery in Europe to robotic in the US bit.ly/3LiqU3c

EV-302 subgroup analysis: Improved outcomes for cisplatin-ineligible advanced #UrothelialCancer patients. Michiel van der Heijden The Netherlands Cancer Institute joins Zach Klaassen Georgia Cancer Center discuss a critical gap in treatment for cisplatin-ineligible patients with advanced UC > bit.ly/3Wb9zPU